Arcturus Therapeutics (ARCT) Holdings announced that the first CF and OTC deficiency participants initiated dosing in December 2024, in the company’s Phase 2 multiple ascending dose studies. “We are very pleased with the recent progress in our Phase 2 studies in people with cystic fibrosis and OTC deficiency. ARCT-032 has the potential to address the significant unmet medical need in the CF community for those who do not qualify for or benefit from available treatment options,” said Dr. Pad Chivukula, Chief Scientific Officer of Arcturus Therapeutics. “ARCT-810 is the only mRNA therapy currently in clinical development intended to enable liver cells to produce OTC enzyme and therefore address the underlying cause of OTC deficiency.”
Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on ARCT:
- Arcturus Therapeutics receives FDA clearance to begin H5N1 vaccine trial
- Arcturus Therapeutics (ARCT): Impressive Pipeline and Potentially Promising Future
- Arcturus Therapeutics Reports Q3 2024 Financial Results and Milestones
- Arcturus Therapeutics reports Q3 EPS (26c), consensus ($1.22)
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
